NORCROSS, Ga., March 27 /PRNewswire-FirstCall/ -- Immucor, Inc. (Nasdaq: BLUD), a global leader in providing automated instrument-reagent systems to the blood transfusion industry, today announced that it expects to release its third quarter earnings on Tuesday, April 1, 2008, after the close of regular trading hours, and then host a conference call on Wednesday, April 2, 2008 at 8:30 AM (EDT) to review the results. Investors are invited to participate in this conference call, with Dr. Gioacchino De Chirico, President and Chief Executive Officer, Richard A. Flynt, Chief Financial Officer, and Edward L. Gallup, consultant. The call will focus on the results for the third quarter and general business trends. The earnings release will be posted on Immucor's website, as well as any material financial information that may be discussed by Dr. De Chirico, Mr. Flynt, or Mr. Gallup during this call that is not contained in the earnings release. Both the earnings release and the additional financial information, if any, will be posted as soon as practicable after the call on the investor news section of Immucor's website. To access this information once posted, go to Immucor's website at http://www.immucor.com and click on "About Us - Press Releases."
To participate in the telephone conference call, dial 1-888-950-8044 and passcode BLUD. Replays of the conference call will be available for one week beginning at 12:00 noon on April 2nd by calling 1-888-568-0013. Beginning April 9, 2008, audio of the conference call or a transcript of the audio will be available on the "About Us - Press Releases" page of the Immucor website.
For more information on Immucor, please visit our website at http://www.immucor.com.
Founded in 1982, Immucor manufactures and sells a complete line of reagents and systems used by hospitals, reference laboratories and donor centers to detect and identify certain properties of the cell and serum components of blood prior to transfusion. Immucor markets a complete family of automated instrumentation for all of its market segments.
|SOURCE Immucor, Inc.|
Copyright©2008 PR Newswire.
All rights reserved